Clin Oncol | Volume 5, Issue 1 | Case Series | Open Access

Interstitial Lung Disease in Abemaciclib-treated Patients during SARS-CoV-2 Pandemic: A Case Series

Barbolini Monica1*, Omarini Claudia2, Toss Angela3, Cortesi Giulia1, Fiorani Claudia2, Piombino Claudia1, Dominici Massimo1 and Piacentini Federico1

1Department of Medical and Surgical Sciences for Children and Adults, University Hospital of Modena, Italy
2Division of Oncology, University Hospital of Modena, Italy
3Division of Medical Oncology, University of Modena and Reggio Emilia, Italy

*Correspondance to: Monica Barbolini 

Fulltext PDF

Abstract

Abemaciclib is a cyclin-dependent 4/6 inhibitor approved by FDA in 2017 and by EMA in 2018 for treatment of hormone receptors positive, HER2 negative metastatic breast cancer in association with endocrine therapy. In 2019 FDA warned for a rare but severe lung inflammation possibly related to CDK 4/6 inhibitors. At the end of 2019 the world comes to know to a new corona virus
causing potential fatal lung injury. Here we report three different cases of interstitial lung disease in patients treated with Abemaciclib during SARS-CoV-2 pandemic at Modena Cancer Center.

Keywords:

COVID-19; Metastatic breast cancer; Abemaciclib; Interstitial lung disease

Citation:

Monica B, Claudia O, Angela T, Giulia C, Claudia F, Claudia P, et al. Interstitial Lung Disease in Abemaciclibtreated Patients during SARS-CoV-2 Pandemic: A Case Series. Clin Oncol. 2020;5:1760..

Subscribe to Our Newsletter